The invention disclosed herein is a novel chronotherapeutic dosage form which consists of controlled release oral pharmaceutical composition comprising poorly acid soluble drug(s) in hydrophilic matrix system, wherein hydrophilic matrix system comprises acid insoluble polymer(s) in combination with pH independent polymer(s) and other pharmaceutically acceptable excipients. The poorly acid soluble drugs and its pharmaceutically acceptable salts are selected from therapeutic categories like nonsteroidal anti-inflammatory drugs (NSAIDs), anthraquinone derivatives, cardiovascular drugs, neurotherapexitic agents, chemotherapeutic agents and drugs acting on endocrine system either alone or in combination. The present invention further describes a process of manufacturing the said chronotherapeutic dosage form.
